TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY FINAL REPORT AND RECOMMENDATIONS

Recommendations

Info

47 3. WE MUST INCREASE THE SUPPLY OF NEW ANTIMICROBIALS EFFECTIVE AGAINST <strong>DRUG</strong>‐<strong>RESISTANT</strong> BUGS We need a better supply of new drugs across a range of diseases where drug resistance is on the rise. We draw out the following needs in order of priority for the main infectious diseases, based on the current level of investment in R&D and the strength of the different pipelines. This order of priorities explains why many of our proposed solutions focus on TB, antibiotics and antifungal medicines. These priorities will change over time as the AMR threat evolves and will need to be reconsidered and resources allocated accordingly. Urgent need and current funding structures inadequate • TB treatment regimen Urgent need but current funding structures largely adequate • New malaria treatments Need will arise and require future consideration • HIV/AIDS drugs But achieving a functioning pipeline will depend on aligning public and private incentives to invest in R&D with public health needs, drawing on the expertise and creativity of research teams in all countries. Opening up the playing field, bringing down barriers to entry into research, and rewarding success wherever it comes from are crucial. “This is important because the supply of discoverable new antimicrobials is not necessarily inexhaustible, whilst their development is increasingly expensive. ” • Antibiotics • Antifungal medicines AMR is inevitable. As people keep finding ways to kill the microbes that infect us, those microbes, through evolutionary processes, will mutate to counteract them. As discussed above, we can reduce the build-up of resistance by reducing unnecessary use of antimicrobials and in particular antibiotics. This is important because the supply of new antimicrobials is not necessarily inexhaustible, whilst their development is increasingly expensive. Even if we manage to reduce the unnecessary use of antimicrobials over the next decade, with a growing world population and continuing improvements in access to healthcare, the world will need a functioning R&D pipeline of new antimicrobials if we are to meet the Sustainable Development Goals (SDGs) agreed in the UN in 2015.
48 INCREASING THE SUPPLY OF ANTIMICROBIALS TO KEEP UP WITH RISING RESISTANCE Drugs • $0.8 to $1.3 billion market entry rewards for antibiotics • International clinical trial platform Global Innovation Fund • A global fund for early-stage research and R&D lacking a commercial imperative Supply Quantity
Page 1 and 2: TACKLING DRUG-RESISTANT INFECTIONS
Page 3 and 4: ACRONYMS AND ABBREVIATIONS AMC Adva
Page 5 and 6: 2 time focusing on this over the la
Page 7 and 8: 4 EXECUTIVE SUMMARY Following 19 mo
Page 9 and 10: 6 7. Improve the numbers, pay and r
Page 11 and 12: 8 Review on Antimicrobial Resistanc
Page 13 and 14: 10 1. THE PROBLEM: WHY TACKLING AMR
Page 15 and 16: 12 This challenge will only get wor
Page 17 and 18: 14 AMR-related research between 200
Page 19 and 20: 16 An outline of the market failure
Page 21 and 22: 18 LOWERING DEMAND FOR ANTIMICROBIA
Page 23 and 24: 20 Labelling of medicines and food:
Page 25 and 26: 22 BETTER WATER AND SANITATION REDU
Page 27 and 28: 24 Intervention 3: Reduce unnecessa
Page 29 and 30: 26 is an issue that the G20 must ta
Page 31 and 32: 28 HOW COUNTRIES COULD ACHIEVE TARG
Page 33 and 34: 30 Reduce Environmental pollution W
Page 35 and 36: 32 Intervention 4: Improve global s
Page 37 and 38: 34 data’ that will be generated a
Page 39 and 40: 36 RAPID DIAGNOSTICS WOULD REDUCE U
Page 41 and 42: 38 NEW RAPID DIAGNOSTICS WOULD OPTI
Page 43 and 44: 40 Intervention 6: Promote developm
Page 45 and 46: 42 ALTERNATIVE PRODUCTS TO TACKLE I
Page 47 and 48: 44 Intervention 7: Improve the numb
Page 49: 46 rising drug resistance as poorer
Page 53 and 54: 50 critical to ensure that efforts
Page 55 and 56: 52 Intervention 9: Better incentive
Page 57 and 58: 54 to emerge more quickly than comm
Page 59 and 60: 56 investment decisions by companie
Page 61 and 62: 58 need to sit on top of and fit wi
Page 63 and 64: 60 Tuberculosis: a cornerstone of t
Page 65 and 66: 62 of a new diagnostic (with no new
Page 67 and 68: 64 4. HOW TO PAY FOR IT: TACKLING A
Page 69 and 70: 66 level, agreements between compan
Page 71 and 72: 68 3. Exchangeable ‘vouchers’ t
Page 73 and 74: 70 antimicrobials and do not incent
Page 75 and 76: IF NOT TACKLED, RISING AMR COULD HA
Page 77 and 78: 74 3.5 3.6 3.7 In 2018, defined tar
Page 79 and 80: 76 ACKNOWLEDGEMENTS The views and o
Page 81 and 82: 78 Dr. Lloyd Czaplewski, Director,
Page 83 and 84: 80 Dr. John Stelling, Co-Director o

TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY FINAL REPORT AND RECOMMENDATIONS

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?